Hunan Fangsheng Pharmaceutical's Bisoprolol Amlodipine Tablet Receives Drug Registration Certificate
Stock News
Mar 04
Hunan Fangsheng Pharmaceutical Co.,Ltd. (603998.SH) announced that on March 3, 2026, its wholly-owned subsidiary, Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd., received the Drug Registration Certificate approved and issued by the National Medical Products Administration. The company's developed Bisoprolol Amlodipine Tablet has obtained the drug approval number and is authorized for production. The drug is indicated as an alternative treatment for hypertension, intended for patients whose blood pressure is well-controlled while currently taking individual drugs at doses equivalent to those in the compound preparation.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.